PTC Therapeutics, Inc.
PTCT Real Time Price USDRecent trades of PTCT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by PTCT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$30,000 Jul 15, 2025 Issue: Health Issues
-
$210,000 Apr 21, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$80,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$500,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$170,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations
-
$170,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations
-
$190,000 Feb 04, 2025 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$570,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$160,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$190,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$200,000 Jul 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$370,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$190,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$180,000 Oct 20, 2021 Issue: None
-
$180,000 Jul 20, 2021 Issue: None
-
$180,000 Apr 20, 2021 Issue: None
-
$180,000 Jan 21, 2021 Issue: None
-
$180,000 Oct 29, 2020 Issue: None
-
$50,000 Jul 20, 2020 Issue: Health Issues
-
$50,000 Apr 26, 2020 Issue: Health Issues
-
$50,000 Feb 25, 2020 Issue: Health Issues
-
$20,000 Apr 17, 2019 Issue: Budget/Appropriations
-
$40,000 Apr 17, 2019 Issue: Budget/Appropriations
-
$30,000 Jan 22, 2019 Issue: Budget/Appropriations
-
$60,000 Jan 22, 2019 Issue: Budget/Appropriations
-
$10,000 Jan 16, 2019 Issue: None
-
$10,000 Oct 18, 2018 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 18, 2018 Issue: Budget/Appropriations
-
$60,000 Oct 18, 2018 Issue: Budget/Appropriations
-
$30,000 Jul 20, 2018 Issue: Budget/Appropriations
-
$60,000 Jul 20, 2018 Issue: Budget/Appropriations
-
$30,000 Apr 20, 2018 Issue: Budget/Appropriations
-
$30,000 Apr 20, 2018 Issue: Budget/Appropriations
-
$30,000 Jan 17, 2018 Issue: Budget/Appropriations
-
$30,000 Jan 17, 2018 Issue: Budget/Appropriations
-
$30,000 Oct 18, 2017 Issue: Budget/Appropriations
-
$30,000 Oct 18, 2017 Issue: Budget/Appropriations
-
$30,000 Aug 09, 2017 Issue: Budget/Appropriations
-
$30,000 Aug 09, 2017 Issue: Budget/Appropriations
-
$30,000 Jul 18, 2017 Issue: Budget/Appropriations
-
$10,000 Apr 20, 2017 Issue: Health Issues
-
$30,000 Apr 19, 2017 Issue: Budget/Appropriations
-
$10,000 Jan 19, 2017 Issue: Budget/Appropriations
-
$30,000 Jan 12, 2017 Issue: Budget/Appropriations
-
$30,000 Oct 20, 2016 Issue: Health Issues
Estimated quarterly lobbying spending
PTCT Revenue by Segment or Geography
New patents grants
-
Patent Title: Heteroaryl compounds for treating huntington's disease Nov. 12, 2024
-
Patent Title: Compounds for treating huntington's disease Oct. 01, 2024
-
Patent Title: Method for treating pancreatic cancer Jul. 02, 2024
-
Patent Title: Polymorphic forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Mar. 26, 2024
-
Patent Title: Heterocyclic and heteroaryl compounds for treating huntington's disease Jan. 02, 2024
-
Patent Title: 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Dec. 12, 2023
-
Patent Title: Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione Oct. 17, 2023
-
Patent Title: Compounds for treating huntington's disease Oct. 10, 2023
-
Patent Title: Compounds for treating spinal muscular atrophy Sep. 12, 2023
-
Patent Title: 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Sep. 05, 2023
-
Patent Title: Methods for modulating rna splicing Jul. 18, 2023
-
Patent Title: Heteroaryl compounds for treating huntington's disease Jun. 27, 2023
-
Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Jun. 20, 2023
-
Patent Title: 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Jun. 06, 2023
-
Patent Title: Methods for treating huntington's disease May. 02, 2023
-
Patent Title: Method of inhibiting or reducing a viral infection Mar. 28, 2023
-
Patent Title: Methods for modifying rna splicing Mar. 21, 2023
-
Patent Title: Methods for modulating rna splicing Mar. 14, 2023
-
Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Jan. 24, 2023
-
Patent Title: Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease Nov. 15, 2022
-
Patent Title: Dhodh inhibitor for use in treating hematologic cancers Oct. 04, 2022
-
Patent Title: Compounds for treating huntington's disease Aug. 09, 2022
-
Patent Title: Methods for treating huntington's disease Jul. 26, 2022
-
Patent Title: 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof Jul. 19, 2022
-
Patent Title: Methods for treating huntington's disease Jul. 12, 2022
-
Patent Title: Process for the production of alpha-tocotrienol and derivatives Apr. 26, 2022
-
Patent Title: Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Apr. 19, 2022
-
Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Nov. 30, 2021
-
Patent Title: Substituted reverse pyrimidine bmi-1 inhibitors Nov. 23, 2021
-
Patent Title: 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Nov. 16, 2021
-
Patent Title: Methods of administering deflazacort therapy Aug. 10, 2021
-
Patent Title: Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers Jun. 01, 2021
-
Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Apr. 20, 2021
-
Patent Title: 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Apr. 06, 2021
-
Patent Title: Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease Mar. 30, 2021
-
Patent Title: Processes for the preparation of substituted tetrahydro beta-carbolines Mar. 16, 2021
-
Patent Title: Gene therapy for aadc deficiency Jan. 26, 2021
-
Patent Title: Methods for treating huntington's disease Jan. 05, 2021
-
Patent Title: Methods for treating huntington's disease Dec. 29, 2020
-
Patent Title: Compounds for treating spinal muscular atrophy Dec. 01, 2020
-
Patent Title: Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy Dec. 01, 2020
-
Patent Title: Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide Aug. 25, 2020
-
Patent Title: Methods for enriching alpha-tocotrienol from mixed tocol compositions Aug. 18, 2020
-
Patent Title: 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof Aug. 11, 2020
-
Patent Title: Treatment of pervasive developmental disorders with redox-active therapeutics Aug. 11, 2020
-
Patent Title: Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders Jul. 07, 2020
-
Patent Title: Methods for modulating the amount of rna transcripts Jun. 23, 2020
-
Patent Title: Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease Jun. 09, 2020
-
Patent Title: Methods for modulating rna splicing Jun. 02, 2020
-
Patent Title: Substituted pyridine and pyrazine bmi-1 inhibitors Mar. 10, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to PTCT
Recent picks made for PTCT stock on CNBC
ETFs with the largest estimated holdings in PTCT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $PTCT stock a Buy, Sell, or Hold?
- What is the price target for $PTCT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $PTCT stock?
- Who owns the most shares of $PTCT stock?
- What funds own $PTCT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PTCT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.